1525TiP - Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of t...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Soft Tissue Sarcomas
Geriatric Oncology
Cancer in Special Situations
Sarcoma
Presenter Bernd Kasper
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors B. Kasper1, P. Reichardt2, M. Schuler3, P. Hohenberger1
  • 1Interdisziplinäres Tumorzentrum, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 2Interdisziplinäre Onkologie, HELIOS Klinikum Berlin-Buch, Berlin-Buch/DE
  • 3Onkologie, HELIOS Klinikum Emil von Behring, Berlin/DE

Abstract

Background

More than half of soft tissue sarcoma (STS) patients are diagnosed older than 60 years and prognosis for advanced disease is unfavourable with a median overall survival (OS) of ∼12 months remaining substantially unchanged during the last 20 years. Quality of Life (QoL), especially when collected directly from the patients as Patient Reported Outcome (PRO) measures, has gained increasing interest in cancer care; however, existing data among elderly STS patients are scarce. The rationale of the E-TRAB study is to analyze QoL and PRO data in the elderly population (aged ≥ 60 years) with advanced STS, considered to be unsuited to receive anthracycline-based chemotherapy, and treated with trabectedin as a 1st line therapy.

Trial design

The E-TRAB (GISG-13) study is designed as a non-interventional trial (n = 110). Primary endpoints to be evaluated are OS and QoL. It is hypothesized that OS will not be 

Clinical trial identification

NCT03022448

Legal entity responsible for the study

GWT-TUD GmbH

Funding

This investigator-initiated (IIT) study was sponsored by GWT-TUD GmbH, Dresden, Germany, with support from PharmaMar, S.A., Madrid, Spain.

Disclosure

B. Kasper: Honoraria and research funding by PharmaMar. P. Reichardt, M. Schuler, P. Hohenberger: Honoraria and research funding from PharmaMar.